Together, these data demonstrate that PTPRZ11814-1822 TCR can broadly and specifically target HLA-A*02+ glioblastoma primary cell lines (5 out of 5) with a preference for stem-like SCCs. The gene discussed is HLA-A; the disease is glioblastoma.